Sebastian Gensior

Probability of Technical Success (PTS) is a metric that evaluates the likelihood that a drug candidate will successfully navigate clinical trials. Unlike broader metrics such as Probability of Success (POS) or Probability of Launch (POL), PTS focuses narrowly on the technical aspects of clinical development, including efficacy, safety, and adherence

The MSCI World Pharmaceuticals, Biotechnology, and Life Sciences Index (USD) is a key benchmark for the biotech and pharmaceutical industry. Comprising 72 large- and mid-cap stocks across 23 markets, this index provides a perspective on companies involved in drug development, biotechnology innovation, and life sciences tools and services. Index

Killing a project is easy. There’s a laundry list of reasons why something “shouldn’t move forward”: it’s too expensive, not aligned with strategy, lacks clear ROI, or simply isn’t the “right time.” Most organizations are primed to find these flaws—whether it’s a risk-averse

LinkedIn profiles boasting titles like ex-McKinsey, ex-Bain, ex-Novartis, or ex-Roche. It’s as if these professionals are collecting exes, not in their personal lives (well, hopefully), but in their résumés, brandishing them like badges of honor.

In European boardrooms, where modesty often masquerades as pragmatism, it is rare for a leader to sound the alarm with the urgency of Mario Draghi. His latest report on the EU pharmaceutical sector paints a stark picture: Europe, once a stalwart in global healthcare, is limping behind its competitors. Without

The Problem with Probability of Success (POS) in Biotech and Pharma Probability of Success (POS) is a widely used metric in biotech and pharma, offering a single probability that a drug candidate will successfully navigate the entire development process, from discovery through preclinical and clinical trials to regulatory approval and

Few metrics in modern oncology trials command the prominence of progression-free survival (PFS). As a measure of time until disease progression or death, PFS is beloved by clinical researchers for its speed and by companies for its clarity in demonstrating efficacy. For regulators, it is a convenient proxy, standing

Brussels has a new plan. The Competitiveness Compass, the European Commission’s latest attempt to reinvigorate the EU economy, comes with a familiar diagnosis: Europe has world-class talent but lacks the capital to scale its own innovations. The remedy? A bold—if somewhat overdue—proposal to mobilize pension funds

For decades, licensing deals have been the biotech-pharma relationship’s bread and butter—a veritable match made in heaven, or at least in a Bunsen burner-lit lab. The formula seems simple: a scrappy biotech develops a potential game-changing therapy, then hands it off to Big Pharma, who

Europe’s biotech sector has always been fond of government grants. Programs like Horizon Europe, with its eye-watering €95.5 billion budget for research and innovation from 2021 to 2027, have kept the pipettes full and the lab coats spotless. National initiatives in Germany and France add to the